Impact Factor
3.93
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.37
949 total citations
h5-index
34
h5 depth signal
Cited share
85.1%
165 of 194
Total citations
949
Citation footprint
Metric signal
4.97
External metric anchor
Self-citation
1.9%
18 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
279
Italy
206
China
99
Netherlands
60
Germany
59
Citing Fields of Research
Pharmacology & Toxicology
356
Cancer Drugs
140
Cardiology
69
Oncology
68
Antibiotic & Antibacterial Agents
59
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,317
Articles tracked across the journal lifetime
Indexed publication set
194
165 cited publications
Last 12 months
70
5.8 publications/month
Open access share
15.7%
11 OA publications in the last year
Leading citing country
United States
279 citing publications
Leading citing field
Pharmacology & Toxicology
356 citing publications
Latest tracked publication
10 October 2026
10 recent records available
Coverage & Indexing History
v1n1, June 2005-
v1n1, June 2005-
Research Focus & Classification
Indexed Subjects
Pharmacology & Toxicology
HIV
Psychiatry
Antibiotic & Antibacterial Agents
Cancer Drugs
Obstetrics/Gynecology
Broad Categories
Metabolism
Toxicology
Pharmacology & Toxicology
Cardiology
Cancer Drugs
HIV
Antibiotic & Antibacterial Agents
Digestive Disorders
MeSH Descriptors
Pharmaceutical Preparations
Toxicology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1080/17425255.2026.2742276
Open DOI
Managing urinary tract infections in pregnancy: teratogenic risks, molecular mechanisms, and antibiotic safety
1. The complex anatomy of the female reproductive system increases susceptibility to pathogen invasion, particularly through the vaginal and rectal regions, making it more prone to opportunistic in...
03
DOI 10.1080/17425255.2026.2742277
Open DOI
How close are we to AI-enabled digital biomarkers in clinical toxicology?
04
DOI 10.1080/17425255.2026.2738611
Open DOI
Computational approaches to predicting xenobiotic metabolism by the human gut microbiota
1. The human gut microbiota comprises more than 1014 bacteria and archaea belonging to approximately 1,100 species, encoding a collective genome 150 times larger than the total human genome [1]. Th...
05
DOI 10.1080/17425255.2026.2738609
Open DOI
Methods of predicting clinically significant DRUG-DRUG interactions beyond validated interaction checkers
1. Drug-drug interactions (DDIs) are among the key factors determining the safety of pharmacotherapy. When two or more drugs are administered simultaneously, one drug may affect the pharmacokinetic...
06
DOI 10.1080/17425255.2026.2733399
Open DOI
Population pharmacokinetic/pharmacodynamic modeling of NH600001 reveals age-related differences in sedation response and supports individualized dosing in elderly patients
1. Safe and effective sedation and anesthesia are crucial components of modern clinical procedures, particularly for short-term surgeries and endoscopic examinations. Etomidate, a widely utilized i...
07
DOI 10.1080/17425255.2026.2729203
Open DOI
Pharmacokinetics of novel drugs for the treatment of diabetic nephropathy
08
DOI 10.1080/17425255.2026.2725922
Open DOI
Preventing drug interactions with antiretrovirals in the aging HIV population: focusing on population pharmacokinetic modeling
1. Substantial gains in survival for people living with human immunodeficiency virus (PLWH) over the past three decades, driven in large part by widespread use of highly effective antiretroviral th...
09
DOI 10.1080/17425255.2026.2726547
Open DOI
The effects of androgens on drug metabolism and transport: clinical pharmacologic considerations for people assigned female at birth
10
DOI 10.1080/17425255.2026.2725917
Open DOI
Pharmacokinetics of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for benign prostatic hyperplasia
1. Benign prostatic hyperplasia (BPH) is a common condition in aging men, in which proliferation of stromal and epithelial cells in the prostate leads to its enlargement [1]. Early work demonstrate...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.